NZ802272A - Methods of treating myelodysplastic syndrome - Google Patents
Methods of treating myelodysplastic syndromeInfo
- Publication number
- NZ802272A NZ802272A NZ802272A NZ80227218A NZ802272A NZ 802272 A NZ802272 A NZ 802272A NZ 802272 A NZ802272 A NZ 802272A NZ 80227218 A NZ80227218 A NZ 80227218A NZ 802272 A NZ802272 A NZ 802272A
- Authority
- NZ
- New Zealand
- Prior art keywords
- myelodysplastic syndrome
- mds
- subject
- methods
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538315P | 2017-07-28 | 2017-07-28 | |
| US201762595329P | 2017-12-06 | 2017-12-06 | |
| US201862685542P | 2018-06-15 | 2018-06-15 | |
| NZ760873A NZ760873B2 (en) | 2018-07-27 | Methods of treating myelodysplastic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ802272A true NZ802272A (en) | 2026-03-27 |
Family
ID=63209674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ802272A NZ802272A (en) | 2017-07-28 | 2018-07-27 | Methods of treating myelodysplastic syndrome |
| NZ802277A NZ802277A (en) | 2017-07-28 | 2018-07-27 | Methods of treating myelodysplastic syndrome |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ802277A NZ802277A (en) | 2017-07-28 | 2018-07-27 | Methods of treating myelodysplastic syndrome |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12171778B2 (https=) |
| EP (1) | EP3658156B1 (https=) |
| JP (4) | JP7316261B2 (https=) |
| KR (2) | KR102867725B1 (https=) |
| CN (2) | CN121243203A (https=) |
| AU (2) | AU2018307983B2 (https=) |
| BR (1) | BR112020001749A2 (https=) |
| CA (1) | CA3069010A1 (https=) |
| CL (2) | CL2020000196A1 (https=) |
| IL (2) | IL324714A (https=) |
| MA (1) | MA49688A (https=) |
| MX (1) | MX2025005894A (https=) |
| NZ (2) | NZ802272A (https=) |
| SG (1) | SG11201913984RA (https=) |
| TW (2) | TWI879717B (https=) |
| UA (1) | UA127701C2 (https=) |
| WO (1) | WO2019023667A1 (https=) |
| ZA (1) | ZA202000070B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| KR102867725B1 (ko) | 2017-07-28 | 2025-10-13 | 제론 코포레이션 | 골수형성이상 증후군의 치료 방법 |
| UA130012C2 (uk) | 2018-11-29 | 2025-10-15 | Джерон Корпорейшн | Спосіб лікування мієлодиспластичного синдрому |
| JP2023534295A (ja) | 2020-07-17 | 2023-08-08 | ジェロン・コーポレーション | 皮下テロメラーゼ阻害剤組成物及びそれらを使用するための方法 |
| CN116887844A (zh) * | 2021-01-18 | 2023-10-13 | 活跃生物技术有限公司 | 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
| US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| CN1317291C (zh) | 1999-09-10 | 2007-05-23 | 杰龙公司 | 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用 |
| US7321029B2 (en) | 2000-01-21 | 2008-01-22 | Geron Corporation | 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| AU2002245717A1 (en) | 2001-03-23 | 2002-10-08 | Geron Corporation | Oligonucleotide conjugates |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| CN100393209C (zh) | 2003-09-09 | 2008-06-11 | 杰龙公司 | 用于端粒酶抑制的改性寡核苷酸 |
| ATE503014T1 (de) | 2003-11-04 | 2011-04-15 | Geron Corp | Rna-amidate und thioamidateur rnai |
| US20050282893A1 (en) | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
| ME02933B (me) | 2004-07-02 | 2018-04-20 | Geron Corp | Sinteza zaštićenih 3'-amino nukleozionih monomera |
| FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| US20060166221A1 (en) | 2005-01-21 | 2006-07-27 | Bahou Wadie F | Methods of diagnosing essential thrombocythemia |
| WO2006113426A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and tubulin activities |
| EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| CA2615574A1 (en) | 2005-07-29 | 2007-02-08 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| US20070224598A1 (en) | 2006-03-15 | 2007-09-27 | The Methodist Hospital Research Institute | System and method for detection of mutations in JAK2 polynucleotides |
| WO2007127163A2 (en) | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
| SI2898887T1 (sl) | 2006-10-30 | 2019-01-31 | Geron Corporation | Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka |
| WO2008094640A2 (en) | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
| US9155753B2 (en) | 2007-03-09 | 2015-10-13 | Geron Corporation | Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors |
| US8367078B2 (en) | 2007-06-06 | 2013-02-05 | University Of Florida Research Foundation, Inc. | Kinase inhibitor compounds |
| CN101220044B (zh) | 2008-01-21 | 2010-06-02 | 中国药科大学 | 端粒酶抑制剂及其制备方法和用途 |
| US8044240B2 (en) | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
| EP2304436A1 (en) | 2008-07-10 | 2011-04-06 | Nodality, Inc. | Methods for diagnosis, prognosis and treatment |
| LT3029154T (lt) | 2008-10-17 | 2017-12-27 | Geron Corporation | Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas |
| WO2011017096A2 (en) | 2009-08-04 | 2011-02-10 | Mayo Foundation For Medical Education And Research | Methods of treating hematologic cancers |
| ES2616055T3 (es) | 2010-02-12 | 2017-06-09 | Qiagen Marseille | ASXL1 como nuevo marcador de diagnóstico de neoplasias mieloides |
| WO2012149339A2 (en) | 2011-04-29 | 2012-11-01 | Sequenom, Inc. | Quantification of a minority nucleic acid species |
| WO2013056211A2 (en) | 2011-10-13 | 2013-04-18 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome |
| WO2013059738A2 (en) | 2011-10-19 | 2013-04-25 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| ES2874774T3 (es) | 2011-12-22 | 2021-11-05 | Geron Corp | Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros |
| CA2892445C (en) | 2012-11-30 | 2022-06-28 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| UA128370C2 (uk) | 2012-12-07 | 2024-06-26 | Джерон Корпорейшн | Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| US20150342982A1 (en) * | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
| US20160022708A1 (en) | 2013-03-14 | 2016-01-28 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of glutamine-addicted cancers |
| PL3065828T3 (pl) * | 2013-11-06 | 2019-06-28 | Mayo Foundation For Medical Education And Research | Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| KR102867725B1 (ko) | 2017-07-28 | 2025-10-13 | 제론 코포레이션 | 골수형성이상 증후군의 치료 방법 |
-
2018
- 2018-07-27 KR KR1020207003450A patent/KR102867725B1/ko active Active
- 2018-07-27 AU AU2018307983A patent/AU2018307983B2/en active Active
- 2018-07-27 MA MA049688A patent/MA49688A/fr unknown
- 2018-07-27 CA CA3069010A patent/CA3069010A1/en active Pending
- 2018-07-27 EP EP18755608.9A patent/EP3658156B1/en active Active
- 2018-07-27 UA UAA202000156A patent/UA127701C2/uk unknown
- 2018-07-27 NZ NZ802272A patent/NZ802272A/en unknown
- 2018-07-27 BR BR112020001749-3A patent/BR112020001749A2/pt not_active Application Discontinuation
- 2018-07-27 SG SG11201913984RA patent/SG11201913984RA/en unknown
- 2018-07-27 KR KR1020257032602A patent/KR20250151565A/ko active Pending
- 2018-07-27 CN CN202511334144.5A patent/CN121243203A/zh active Pending
- 2018-07-27 TW TW107126009A patent/TWI879717B/zh active
- 2018-07-27 WO PCT/US2018/044225 patent/WO2019023667A1/en not_active Ceased
- 2018-07-27 JP JP2020504178A patent/JP7316261B2/ja active Active
- 2018-07-27 NZ NZ802277A patent/NZ802277A/en unknown
- 2018-07-27 US US16/047,502 patent/US12171778B2/en active Active
- 2018-07-27 CN CN201880049391.2A patent/CN110944646A/zh active Pending
- 2018-07-27 IL IL324714A patent/IL324714A/en unknown
- 2018-07-27 TW TW113103931A patent/TWI906757B/zh active
-
2020
- 2020-01-06 ZA ZA2020/00070A patent/ZA202000070B/en unknown
- 2020-01-21 IL IL272163A patent/IL272163B1/en unknown
- 2020-01-23 CL CL2020000196A patent/CL2020000196A1/es unknown
- 2020-01-24 MX MX2025005894A patent/MX2025005894A/es unknown
-
2021
- 2021-04-28 CL CL2021001096A patent/CL2021001096A1/es unknown
-
2022
- 2022-11-16 JP JP2022183229A patent/JP7654615B2/ja active Active
-
2023
- 2023-11-21 JP JP2023197448A patent/JP7654761B2/ja active Active
-
2024
- 2024-09-20 AU AU2024219941A patent/AU2024219941A1/en active Pending
- 2024-11-12 JP JP2024197684A patent/JP2025013669A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202000070B (en) | Methods of treating myelodysplastic syndrome | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX382902B (es) | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. | |
| ZA201903327B (en) | Compositions and methods for the induction of cd8+ t¿cells | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
| ZA201800056B (en) | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders | |
| MX2017005929A (es) | Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit. | |
| MA39817A (fr) | Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40 | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| EP4389142A3 (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| MX2018002344A (es) | Metodo para tratar el cancer. | |
| MX2024014239A (es) | Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer | |
| MX2018014610A (es) | Uso de un anticuerpo anti proteina de muerte programada 1 (pd-1) en combinacion con un anticuerpo anti cumulo de diferenciacion 3d (cd30) en el tratamiento del linfoma. | |
| PH12019501945B1 (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
| MX2021006326A (es) | Inhibidores de pcna. | |
| MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
| MX2019005089A (es) | Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso. | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| EP4417259A3 (en) | Compositions and methods for prevention and treatment of corneal haze and scarring | |
| PH12021550376A1 (en) | Combination therapy | |
| PH12021550035A1 (en) | Combination therapy | |
| MX2020012805A (es) | Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos. | |
| CL2021001386A1 (es) | Métodos de tratamiento del síndrome mielodisplásico |